Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVONASDAQ:PLTRNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$79.90-1.4%$67.30$57.00▼$148.15$363.71B0.667.04 million shs7.47 million shsPLTRPalantir Technologies$137.40+1.6%$115.48$21.23▼$140.00$324.25B2.6481.02 million shs93.32 million shsUTHRUnited Therapeutics$283.35-1.0%$300.50$266.98▼$417.82$12.78B0.57452,793 shs564,424 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S0.00%+6.97%+20.94%+3.47%-44.24%PLTRPalantir Technologies0.00%+7.58%+7.24%+59.32%+478.04%UTHRUnited Therapeutics0.00%-13.03%-6.77%-7.78%+0.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNVONovo Nordisk A/S4.6227 of 5 stars4.13.02.50.02.20.04.4PLTRPalantir Technologies2.3791 of 5 stars2.05.00.00.02.22.51.3UTHRUnited Therapeutics4.9913 of 5 stars4.35.00.04.62.93.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVONovo Nordisk A/S 2.27Hold$112.0040.17% UpsidePLTRPalantir Technologies 1.91Reduce$86.30-37.19% DownsideUTHRUnited Therapeutics 2.69Moderate Buy$393.0838.72% UpsideCurrent Analyst Ratings BreakdownLatest PLTR, NVO, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PLTRPalantir TechnologiesLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $155.006/11/2025PLTRPalantir TechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$94.00 ➝ $116.006/11/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$321.00 ➝ $315.006/2/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$405.005/8/2025PLTRPalantir TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$110.00 ➝ $115.005/6/2025PLTRPalantir TechnologiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform5/6/2025PLTRPalantir TechnologiesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell5/6/2025PLTRPalantir TechnologiesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$140.005/6/2025PLTRPalantir TechnologiesLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$125.00 ➝ $130.005/6/2025PLTRPalantir TechnologiesDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$100.00 ➝ $115.005/6/2025PLTRPalantir TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$80.00 ➝ $90.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVONovo Nordisk A/S$303.14B1.18$3.70 per share21.57$4.64 per share17.22PLTRPalantir Technologies$3.12B104.09$0.12 per share1,121.92$2.24 per share61.34UTHRUnited Therapeutics$2.99B4.27$17.04 per share16.63$127.35 per share2.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVONovo Nordisk A/S$14.64B$3.3824.2917.150.9034.81%84.68%26.29%8/6/2025 (Estimated)PLTRPalantir Technologies$462.19M$0.23723.20404.1210.8416.13%6.85%5.48%8/4/2025 (Estimated)UTHRUnited Therapeutics$984.80M$25.0612.4410.310.9740.31%19.22%16.15%7/30/2025 (Estimated)Latest PLTR, NVO, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025NVONovo Nordisk A/S$0.92$0.92N/A$0.92N/A$11.87 billion5/5/2025Q1 2025PLTRPalantir Technologies$0.13$0.13N/A$0.08$863.89 million$883.86 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVONovo Nordisk A/S$1.632.04%N/A48.22%N/APLTRPalantir TechnologiesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVONovo Nordisk A/S0.620.740.55PLTRPalantir TechnologiesN/A5.965.67UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVONovo Nordisk A/S11.54%PLTRPalantir Technologies45.65%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipNVONovo Nordisk A/S0.07%PLTRPalantir Technologies9.23%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVONovo Nordisk A/S54,4004.49 billion4.48 billionOptionablePLTRPalantir Technologies3,9362.36 billion1.98 billionOptionableUTHRUnited Therapeutics98045.11 million39.33 millionOptionablePLTR, NVO, and UTHR HeadlinesRecent News About These Companies328,783 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Vaughan Nelson Investment Management L.P.June 15 at 5:55 AM | marketbeat.comSG Americas Securities LLC Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)June 14 at 4:05 AM | marketbeat.comTobam Sells 11,834 Shares of United Therapeutics Co. (NASDAQ:UTHR)June 13 at 6:23 AM | marketbeat.com3,900 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Polianta LtdJune 13 at 5:54 AM | marketbeat.comGreenwood Capital Associates LLC Acquires Shares of 2,349 United Therapeutics Co. (NASDAQ:UTHR)June 13 at 5:26 AM | marketbeat.comAssenagon Asset Management S.A. Purchases 10,290 Shares of United Therapeutics Co. (NASDAQ:UTHR)June 13 at 4:36 AM | marketbeat.comUnited Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?June 13 at 3:36 AM | zacks.comBank of America Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $315.00June 13 at 1:19 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Cut to $315.00 by Analysts at Bank of AmericaJune 11, 2025 | marketbeat.comUnited Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying StockJune 11, 2025 | seekingalpha.comUnited Therapeutics: Strong Market Position and Growth Potential Amidst Emerging CompetitionJune 11, 2025 | tipranks.comJames Edgemond Sells 12,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockJune 10, 2025 | marketbeat.comInsmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial ResultsJune 10, 2025 | msn.comUnited Therapeutics (NASDAQ:UTHR) Shares Gap Down - Here's What HappenedJune 10, 2025 | marketbeat.comAtwood & Palmer Inc. Sells 879 Shares of United Therapeutics Co. (NASDAQ:UTHR)June 10, 2025 | marketbeat.comCantor Fitzgerald Forecasts UTHR FY2026 EarningsJune 10, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Holdings Raised by Nepsis Inc.June 10, 2025 | marketbeat.comLiquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH assetJune 10, 2025 | seekingalpha.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Livforsakringsbolaget Skandia OmsesidigtJune 10, 2025 | marketbeat.comToth Financial Advisory Corp Has $404,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)June 10, 2025 | marketbeat.comQ2 EPS Forecast for United Therapeutics Boosted by AnalystJune 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomePalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?Palantir: AI Leadership and Rising Analyst ExpectationsBy Chris Markoch | May 20, 2025View Palantir: AI Leadership and Rising Analyst ExpectationsRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?Palantir Stock Holds Support, Despite Political BacklashBy Chris Markoch | June 9, 2025View Palantir Stock Holds Support, Despite Political BacklashPLTR, NVO, and UTHR Company DescriptionsNovo Nordisk A/S NYSE:NVO$79.90 -1.15 (-1.42%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$80.01 +0.11 (+0.14%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Palantir Technologies NASDAQ:PLTR$137.40 +2.21 (+1.63%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$137.65 +0.25 (+0.18%) As of 06/13/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates under the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.United Therapeutics NASDAQ:UTHR$283.35 -2.79 (-0.98%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$282.38 -0.98 (-0.34%) As of 06/13/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
